Chromogranin A in pituitary adenomas: immunohistochemical detection and plasma concentrations. by Pawlikowski, Marek et al.
FOLIA HISTOCHEMICA
ET CYTOBIOLOGICA
Vol. 42, No. 4, 2004
pp. 245-247
Chromogranin A in pituitary adenomas:
immunohistochemical detection and plasma
concentrations
Marek Pawlikowski1, Anna Gruszka1, Maciej Radek3 and Jolanta Kunert-Radek2 
1Department of Experimental Endocrinology and Hormone Diagnostics, 2Department of Clinical
Endocrinology, Institute of Endocrinology, and 3Department of Neurosurgery and Surgery of Peripheral
Nerves, Medical University, Łódz´, Poland
Abstract: Forty one pituitary adenomas excised surgically were immunostained to reveal pituitary hormones and chromogranin
A (CgA). In 23 patients, plasma CgA concentration was determined before surgery by ELISA method. The CgA immunoposi-
tivity was found in 70.7% of investigated tumors. It was observed in all tumors of gonadotropinoma type and in the majority
of null cell adenomas. Elevated (>18 U/L) plasma CgA concentration was observed in approx. a half of the examined patients,
being more frequent in gonadotropinomas and null cell adenomas. It may have some, although limited, diagnostic value in
these types of pituitary tumors.
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Introduction
Chromogranin A (CgA) is a glycoprotein present in
granules of neuroendocrine cells. It is abundantly ex-
pressed in neuroendocrine tumors, such as pheochro-
mocytomas, gastrinomas, neuroblastomas, thyroid
medullary cancers and carcinoid tumors and its plas-
ma levels serves as marker of these tumors [2, 7, 10].
CgA immunopositivity is also an useful marker in
histopathological diagnosis of neuroendocrine tumors
[6]. It is also a marker of neuroendocrine differentia-
tion of the non-endocrine cancers. CgA may be also
expressed in pituitary adenomas [1, 4, 8, 13]. How-
ever, its relation to pituitary adenoma hormonal
profile and outcome is not fully established, mainly
because of limited series of investigated tumors. Plas-
ma CgA concentrations were also investigated in pa-
tients with pituitary tumors but its usefulness as
pituitary tumor marker is questionable [3, 5, 9]. The
aim of the present study was to answer the following
questions: (1) Does CgA immunopositivity depend on
the hormonal immunotype of pituitary adenoma? (2)
Is CgA tumor immunopositivity accompanied by elev-
ated preoperative plasma CgA levels? (3) Can plasma
CgA levels be a presurgical marker of pituitary adeno-
mas (or of their specific types)?
Materials and methods
Forty one surgically excised pituitary adenomas were investi-
gated. The diagnosis was based on preoperative clinical obser-
vation including pituitary hormone measurement in blood serum
followed by histopathological and immunohistochemical exam-
ination of the excised tumor fixed in Bouin-Hollande fixative.
The latter was performed on paraffin sections using the anti-
bodies against pituitary hormones or their subunits. The follow-
ing pituitary adenomas were included into study: 14 gonado-
tropinomas, 5 prolactinomas, 5 somatotropinomas co-secreting
prolactin (somatoprolactinomas), 8 corticotropinomas (5 with
Cushing disease and 3 without clinical symptomatology of
hypercorticism), and 9 tumors immunonegative for all the inves-
tigated pituitary hormones (null cell adenomas). The adenomas
immunopositive for FSH, LH or free alpha-subunit were all
classified as gonadotropinomas following Trouillas et al. [14].
Chromogranin A immunoreactivity was investigated on paraffin
sections using the prediluted polyclonal anti-human chromo-
granin A antibody (Dako, code H0085). The binding of primary
antibody was detected using anti-rabbit IgG biotinylated goat
antibody, streptavidin complex (Strept ABC/HRP, Dako) and
3,3’-diaminobenzidine.
Plasma concentrations of CgA were measured before surgery in
23 patients by using Chromogranin A ELISA Kit (DakoCytomation,
Denmark).
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Results and discussion
CgA immunopositivity was found in 29 out of 41 exam-
ined tumors (70.7%). The localization of immunostain-
ing - on the cell periphery (Fig. 1) - was roughly similar
in all CgA-immunopositive adenomas. The positive im-
munostaining was present in all (14/14) gonadotropino-
mas and in the majority of null cell adenomas (7/9). In
corticotropinomas the chromogranin immunopositivity
was observed in a half of tumors (4/8; including 3/5 of
tumors causing the Cushing disease and 1/3 "silent"
corticotropinomas). In contrast, CgA immunopositivity
was rarely observed in mixed GH/PRL-secreting adeno-
mas (somatoprolactinomas) and in prolactinomas (2/5 in
both groups).
Before surgery, plasma CgA concentrations were
elevated over the normal values established by the
manufacturer of the ELISA kit (2-18 U/L) in 11/23 of
the investigated patients. The elevated levels were noted
in 6/9 patients with gonadotropinomas, 3/4 null cell
adenomas,1/2 prolactinomas, 1/4 somatoprolactinomas
and in none of 4 investigated patients with corticotropi-
nomas. The mean concentration of plasma CgA was
slightly higher in patients with chromogranin-immuno-
positive adenomas (26.5±25.5 U/L) than in those with
chromogranin-immunonegative tumors (18.5±13.4
U/L) but the difference was statistically insignificant. In
two cases, the plasma CgA levels were elevated in spite
of the negative immunoreaction in tumors. The highest
mean value was observed in patients with gonadotropi-
nomas (37.5±35.4 U/L) and the lowest in somatoprolac-
tinomas (8.4±6.2 U/L, see Fig. 2). However, the
differences are not statistically significant probably be-
cause of limited number of determinations. Since only
two measurements were done in prolactinomas, the
mean value was not calculated for this subtype of tumor.
The data presented above confirm the earlier findings
that pituitary adenomas can express chromogranin A.
The CgA immunopositivity is a regular phenomenon in
gonadotropinomas - which corroborates with earlier un-
published observations of J.Trouillas (personal com-
munication) - and in null cell adenomas. Our data also
agree with those of Colombo et al. [1] who found posi-
tive immunoscintigraphy with anti-chromogranin A
antibody in the majority of non-functioning pituitary
adenomas (9/11) but only in 1/4 growth hormone secret-
ing tumors. The CgA expression in pituitary adenomas,
as revealed by immunohistochemistry, is usually accom-
panied by the elevated CgA levels in plasma. However,
the elevation is rather moderate and not regular. In some
cases, the plasma CgA levels were within normal range
in spite of marked chromogranin immunostaining in the
tumor. In contrast, in two cases the plasma CgA concen-
trations were elevated in spite of the lack of immunos-
taining in the tumor. The latter finding can be explained
either by the co-existence of the occult extra-pituitary
neuroendocrine tumor or by the action of other factors
which can influence the plasma CgA (for instance, the
Fig. 1. Chromogranin A immuno-
staining in gonadotropinoma (free
alpha subunit immunopositive
adenoma) in 39 yrs old man. × 400.
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sympathetic hyperactivity). Our findings support the view
that the role of CgA plasma determination is of limited
value as a pituitary adenoma marker [3, 5, 9]. However,
the elevation of CgA, although moderate, occurs mainly in
gonadotropinomas and null cell adenomas. These tumors
clinically manifest as non-functioning and their early diag-
nosis is very difficult [11, 12]. Thus, even a moderate
elevation of plasma CgA concentration should be a signal
justifying search for a pituitary tumor. 
The usefulness of plasma CgA monitoring after
surgery in patients with chromogranin-immunopositive
pituitary adenomas in order to evaluate the radicality of
the operation and to predict tumor recurrence is very
probable but needs further prospective studies.
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Fig. 2. Mean (SD) plasma chromogranin A concentrations in patients
with different subtypes of pituitary adenoma. GON - gonadotropino-
ma; NCA- null cell adenoma; ACTH - corticotropinoma; GH/PRL -
somatoprolactinoma.
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